These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 29635903)

  • 41. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
    Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
    J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vernonia cinerea Less. inhibits tumor cell invasion and pulmonary metastasis in C57BL/6 mice.
    Pratheeshkumar P; Kuttan G
    Integr Cancer Ther; 2011 Jun; 10(2):178-91. PubMed ID: 21059623
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Synergic effects of the combination of VEGF-targeted shRNA and taxol on human prostate cancer DU145 both in vitro and in vivo].
    Li BW; Zhang M; He HW; Zhang SH; Shao RG
    Yao Xue Xue Bao; 2009 Mar; 44(3):296-302. PubMed ID: 19449527
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2.
    Witt D; Burfeind P; von Hardenberg S; Opitz L; Salinas-Riester G; Bremmer F; Schweyer S; Thelen P; Neesen J; Kaulfuss S
    Carcinogenesis; 2013 May; 34(5):1115-24. PubMed ID: 23349020
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis.
    Ko CJ; Lan SW; Lu YC; Cheng TS; Lai PF; Tsai CH; Hsu TW; Lin HY; Shyu HY; Wu SR; Lin HH; Hsiao PW; Chen CH; Huang HP; Lee MS
    Oncogene; 2017 Aug; 36(32):4597-4609. PubMed ID: 28368394
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
    Muñoz-Moreno L; Arenas MI; Schally AV; Fernández-Martínez AB; Zarka E; González-Santander M; Carmena MJ; Vacas E; Prieto JC; Bajo AM
    Int J Cancer; 2013 Feb; 132(4):755-65. PubMed ID: 22777643
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prostate cancer cells home to bone using a novel in vivo model: modulation by the integrin antagonist GLPG0187.
    Reeves KJ; Hurrell JE; Cecchini M; van der Pluijm G; Down JM; Eaton CL; Hamdy F; Clement-Lacroix P; Brown NJ
    Int J Cancer; 2015 Apr; 136(7):1731-40. PubMed ID: 25156971
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Consistency of a dialyzable leucocyte extract manufactured at GMP facilities by nuclear magnetic resonance spectroscopy.
    Herbert-Pucheta JE; López-Morales CA; Medina-Rivero E; Estrada-Parra S; Pérez-Tapia SM; Zepeda-Vallejo LG
    J Pharm Biomed Anal; 2021 Mar; 196():113940. PubMed ID: 33549874
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling.
    Verma A; Artham S; Alwhaibi A; Adil MS; Cummings BS; Somanath PR
    Biochem Pharmacol; 2020 Jul; 177():113943. PubMed ID: 32240651
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect in vivo and in vitro treatment with dialyzable leukocyte extracts on human natural killer cell activity.
    Lang I; Nékám K; Gergely P; Petrányi G
    Clin Immunol Immunopathol; 1982 Oct; 25(1):139-44. PubMed ID: 7151336
    [No Abstract]   [Full Text] [Related]  

  • 51. In vitro and in vivo studies of the target cell for dialyzable leukocyte extracts. Evidence for recipient specificity.
    Arala-Chaves MP; Silva A; Porto MT; Picoto A; Ramos MT; Fudenberg HH
    Clin Immunol Immunopathol; 1977 Nov; 8(3):430-47. PubMed ID: 912945
    [No Abstract]   [Full Text] [Related]  

  • 52. Immunotherapies inducing immunogenic cell death in cancer: insight of the innate immune system.
    Calvillo-Rodríguez KM; Lorenzo-Anota HY; Rodríguez-Padilla C; Martínez-Torres AC; Scott-Algara D
    Front Immunol; 2023; 14():1294434. PubMed ID: 38077402
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Co-Treatment with Human Leukocyte Extract and Albendazole Stimulates Drug's Efficacy and Th1 Biased Immune Response in
    Hrčková G; Mačak Kubašková T; Mudroňová D; Jurčacková Z; Ciglanová D
    Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839863
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumor-Derived Exosomes Modulate Primary Site Tumor Metastasis.
    Bai S; Wang Z; Wang M; Li J; Wei Y; Xu R; Du J
    Front Cell Dev Biol; 2022; 10():752818. PubMed ID: 35309949
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sequencing Analysis and Identification of the Primary Peptide Component of the Dialyzable Leukocyte Extract "Transferon Oral": The Starting Point to Understand Its Mechanism of Action.
    Vallejo-Castillo L; Favari L; Vázquez-Leyva S; Mellado-Sánchez G; Macías-Palacios Z; López-Juárez LE; Valencia-Flores L; Medina-Rivero E; Chacón-Salinas R; Pavón L; Pérez-Tapia SM
    Front Pharmacol; 2020; 11():569039. PubMed ID: 33117165
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhancing innate immunity against virus in times of COVID-19: Trying to untangle facts from fictions.
    Larenas-Linnemann D; Rodríguez-Pérez N; Arias-Cruz A; Blandón-Vijil MV; Del Río-Navarro BE; Estrada-Cardona A; Gereda JE; Luna-Pech JA; Navarrete-Rodríguez EM; Onuma-Takane E; Pozo-Beltrán CF; Rojo-Gutiérrez MI
    World Allergy Organ J; 2020 Nov; 13(11):100476. PubMed ID: 33072240
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bovine Dialyzable Leukocyte Extract IMMUNEPOTENT-CRP Induces Selective ROS-Dependent Apoptosis in T-Acute Lymphoblastic Leukemia Cell Lines.
    Lorenzo-Anota HY; Martínez-Torres AC; Scott-Algara D; Tamez-Guerra RS; Rodríguez-Padilla C
    J Oncol; 2020; 2020():1598503. PubMed ID: 32587616
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Validation of a Cell Proliferation Assay to Assess the Potency of a Dialyzable Leukocyte Extract Intended for Batch Release.
    Carballo-Uicab G; Linares-Trejo JE; Mellado-Sánchez G; López-Morales CA; Velasco-Velázquez M; Pavón L; Estrada-Parra S; Pérez-Tapia SM; Medina-Rivero E
    Molecules; 2019 Sep; 24(19):. PubMed ID: 31547184
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The dialyzable leukocyte extract Transferon
    Hernández-Esquivel MA; Pérez-Torres A; Romero-Romero L; Reyes-Matute A; Loaiza B; Mellado-Sánchez G; Pavón L; Medina-Rivero E; Pestell RG; Pérez-Tapia SM; Velasco-Velázquez MA
    Biomed Pharmacother; 2018 May; 101():938-944. PubMed ID: 29635903
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Herpes murine model as a biological assay to test dialyzable leukocyte extracts activity.
    Salinas-Jazmín N; Estrada-Parra S; Becerril-García MA; Limón-Flores AY; Vázquez-Leyva S; Medina-Rivero E; Pavón L; Velasco-Velázquez MA; Pérez-Tapia SM
    J Immunol Res; 2015; 2015():146305. PubMed ID: 25984538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.